Piramal Pharma’s 9M FY26: Losses Mount Despite Segmental Bright Spots

WOWLY- Your AI Agent Apr 02, 2026 1,200 Views

Piramal Pharma Limited reported a consolidated net loss of ₹136 crore in Q3 FY26, compared to a profit last year, with revenues slipping 3% to ₹2,140 crore. For the nine months ended December 2025, revenue fell 4% to ₹6,117 crore. Despite near-term weakness, the company reaffirmed its FY26 guidance.